Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET

Company Participants

Martin Auster - Chief Financial Officer
Raju Mohan - Founder and Chief Executive Officer
John Nuss - Chief Scientific Officer

Conference Call Participants

Liam Hiester - Piper Sandler
Emily Bodnar - H.C. Wainwright
Gospel Enyindah-Asonye - Morgan Stanley
Alex Thompson - Stifel
Derek Archila - Wells Fargo
Sam Slutsky - Life Science

Operator

Good afternoon, ladies and gentlemen and welcome to the Ventyx Biosciences First Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to Dr. Martin Auster, Ventyx’ Chief Financial Officer. Please begin.

Martin Auster

Thank you, operator, and good afternoon to everyone joining us today. Welcome to Ventyx Biosciences conference call webcast where we’ll be discussing our first quarter 2024 financial results and providing a corporate update.

Before we begin, I would like to remind everyone that today’s presentations will include forward-looking statements. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. A description of these risks can be found in our Form 10-Q for the quarter ended March 31, 2024, which was just recently filed this afternoon. Any forward-looking statements are made only as of today’s date, and we assume no obligation to update any forward-looking statements made on today’s call.

With that, I’ll hand the call over now to Dr. Raju Mohan, Ventyx’ Founder and CEO. Raju, please go ahead.

Raju Mohan

Yes. Thanks, Marty, and thank you, everyone, for joining us for our first quarter 2024 earnings call and corporate update. As we recently provided a full pipeline and strategic update at our March Investor Day, I will be brief with my remarks today. Let me take a few minutes to provide some high-level comments on the status of our pipeline programs, and then I’ll hand the call back to Marty to review our first quarter financial results. We’ll then open the floor to Q&A, where I’ll be again joined by Marty and also with John Nuss, our Chief Scientific Officer.

So I’ll begin with our portfolio of potential best-in-class NLRP3 inhibitors. In March, we announced positive top line results from a Phase 1 single- and multiple-ascending dose trial of VTX3232, our novel CNS-penetrant NLRP3 inhibitor in adult healthy volunteers. As you may remember, repeat VTX3232 doses as low as 3 milligrams once daily achieved steady-state IL-1 beta IC50 coverage in both plasma and the CSF and repeat doses of 20 milligrams all the way up to 40 milligrams QD, well exceeded IL-1 beta IC90 coverage in both plasma and CSF.